Patents by Inventor Daniel J. Sexton

Daniel J. Sexton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS
    Publication number: 20220170936
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: October 1, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Metabolite biomarkers for diseases associated with the contact activation system
    Patent number: 11340237
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 24, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA
    Publication number: 20220033521
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Application
    Filed: June 11, 2021
    Publication date: February 3, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Methods of determining levels of cleaved and/or intact kininogen
    Patent number: 11156612
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION
    Publication number: 20210322972
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Application
    Filed: November 24, 2020
    Publication date: October 21, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20210309741
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: March 17, 2021
    Publication date: October 7, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • PROTEIN BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20210285962
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: September 15, 2017
    Publication date: September 16, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • IMMUNOASSAY TO DETECT CLEAVED HIGH MOLECULAR WEIGHT KININOGEN
    Publication number: 20210270842
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
    Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIA
    Publication number: 20210230299
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Application
    Filed: December 29, 2020
    Publication date: July 29, 2021
    Applicant: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Compositions and methods for treatment of diabetic macular edema
    Patent number: 11046785
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 29, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
    Patent number: 11014988
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 25, 2021
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20210087293
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 25, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Monoclonal antibody inhibitor of factor XIIA
    Patent number: 10913802
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Immunoassay to detect cleaved high molecular weight kininogen
    Patent number: 10914747
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK
    Publication number: 20210025898
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Application
    Filed: December 15, 2016
    Publication date: January 28, 2021
    Applicant: Dyax Corp.
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
    Patent number: 10870115
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: December 22, 2020
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette
  • DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20200371120
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 26, 2020
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • Diagnosis and treatment of autoimmune diseases
    Patent number: 10648990
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 12, 2020
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA
    Publication number: 20200115469
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Application
    Filed: August 15, 2019
    Publication date: April 16, 2020
    Applicant: Dyax Corp.
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton